178 related articles for article (PubMed ID: 21990394)
1. Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
Jabbour E; Kantarjian HM; O'Brien S; Shan J; Quintás-Cardama A; Garcia-Manero G; Rios MB; Cortes JE
J Clin Oncol; 2011 Nov; 29(32):4260-5. PubMed ID: 21990394
[TBL] [Abstract][Full Text] [Related]
2. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Jabbour E; Kantarjian H; O'Brien S; Shan J; Quintas-Cardama A; Faderl S; Garcia-Manero G; Ravandi F; Rios MB; Cortes J
Blood; 2011 Oct; 118(17):4541-6; quiz 4759. PubMed ID: 21803854
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
8. Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
DeAngelo DJ; Chen L; Guerin A; Styles A; Giguere-Duval P; Wu EQ
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):245-51. PubMed ID: 24393622
[TBL] [Abstract][Full Text] [Related]
9. Practical monitoring of chronic myelogenous leukemia: when to change treatment.
Saglio G; Fava C
J Natl Compr Canc Netw; 2012 Jan; 10(1):121-9. PubMed ID: 22223872
[TBL] [Abstract][Full Text] [Related]
10. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
Jabbour E; Kantarjian H; Ghanem H; O'Brien S; Quintas-Cardama A; Garcia-Manero G; Cardenas M; Cortes J
Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):302-6. PubMed ID: 23318257
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Ohanian M; Kantarjian HM; Quintas-Cardama A; Jabbour E; Abruzzo L; Verstovsek S; Borthakur G; Ravandi F; Garcia-Manero G; Champlin R; Pierce S; Alattar ML; Trinh LX; Luthra R; Ferrajoli A; Kadia T; O'Brien S; Cortes JE
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):155-162.e1. PubMed ID: 24332214
[TBL] [Abstract][Full Text] [Related]
12. A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K; Akagi T; Shimosegawa K; Sugawara T; Ishizawa K; Ito S; Murai K; Motegi M; Yokoyama H; Noji H; Tajima K; Kimura J; Chou T; Ogawa K; Harigae H; Kubo K; Oba K; Sakamoto J; Ishida Y
Eur J Haematol; 2015 Dec; 95(6):558-65. PubMed ID: 25703064
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
Firwana B; Sonbol MB; Diab M; Raza S; Hasan R; Yousef I; Zarzour A; Garipalli A; Doll D; Murad MH; Al-Kali A
Int J Cancer; 2016 Mar; 138(6):1545-53. PubMed ID: 26455714
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
[TBL] [Abstract][Full Text] [Related]
15. Response dynamics in chronic-phase chronic myeloid leukemia.
Mauro MJ
Clin Lymphoma Myeloma; 2009 Jun; 9(3):217-22. PubMed ID: 19525190
[TBL] [Abstract][Full Text] [Related]
16. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Kantarjian H; O'Brien S; Jabbour E; Shan J; Ravandi F; Kadia T; Faderl S; Garcia-Manero G; Borthakur G; Cortes J
J Clin Oncol; 2011 Aug; 29(23):3173-8. PubMed ID: 21747082
[TBL] [Abstract][Full Text] [Related]
17. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
Cortes J; Quintas-Cardama A; Jabbour E; O'Brien S; Verstovsek S; Borthakur G; Ravandi F; Garcia-Manero G; Burton E; Shan J; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):421-6. PubMed ID: 21831744
[TBL] [Abstract][Full Text] [Related]
18. Fluorescent In Situ Hybridization Monitoring and Effect of Detected Early Responses in the Outcome of Patients With Chronic Phase Chronic Myeloid Leukemia: A Report From a Latin American Country.
Bourlon C; Hernandez-Mata C; Vargas-Serafín C; Bourlon MT; Tuna-Aguilar E; Aguayo A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):453-9. PubMed ID: 27259590
[TBL] [Abstract][Full Text] [Related]
19. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
Cortes JE; Baccarani M; Guilhot F; Druker BJ; Branford S; Kim DW; Pane F; Pasquini R; Goldberg SL; Kalaycio M; Moiraghi B; Rowe JM; Tothova E; De Souza C; Rudoltz M; Yu R; Krahnke T; Kantarjian HM; Radich JP; Hughes TP
J Clin Oncol; 2010 Jan; 28(3):424-30. PubMed ID: 20008622
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation.
Kim D; Goh HG; Kim SH; Choi SY; Park SH; Jang EJ; Kim DW
Int J Hematol; 2012 Jul; 96(1):47-57. PubMed ID: 22610512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
